Synergy's plecanatide hits mark in second Phase III

Synergy Pharmaceuticals Inc. (NASDAQ:SGPY) gained $1.03 (22%) to $5.77 on Friday following its after-hours announcement on Thursday that plecanatide (formerly SP-304) met the primary endpoint of a second Phase III trial to treat irritable bowel syndrome with constipation (IBS-C). Earlier this month, Synergy reported results of the first Phase III study, in which plecanatide also met the primary endpoint.

The guanylate cyclase C (GCC; GUCY2C) agonist is under FDA review to treat chronic idiopathic constipation (CIC), with a Jan. 29 PDUFA date. Synergy plans to file an sNDA in 1Q17 to treat IBS-C...